Frontlight ResearchEarly access
Taking peoplePhase 4
Avian influenza vaccine immunity
Key facts
- Who runs it
- Finnish Institute For Health And Welfare
- Where
- Finland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 300 people, planned
- Started
- 26 Jun 2024
- Expected to end
- 31 Dec 2034
- Type of study
- Interventional
- Record updated
- 21 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 18 to 65 years
- Belongs to the target group of the avian influenza vaccine
- Is planning to receive at least one dose of the avian influenza vaccine
- Is able to understand the given written and oral information
- Has given written informed consent
- Home address in Finland
- Is able to give samples 3 weeks after each vaccine dose and preferably also participate in the follow-up at 6 and 12 months
- Pregnant and lactating women can participate in the study
Who cannot take part
- None
This trial is currently available in Finland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this study is to evaluate the humoral and cell-mediated immune responses induced by the customized avian influenza vaccine, specifically against the H5N1 2.3.4.4b clade.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Avian and seasonal influenza vaccine induced immune responses
- Record updated
- 21 January 2026